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Background/Aims: Limited options remain for patients with metastatic colorectal cancer (CRC) after failure of
standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI)
has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The pre-
sent study was conducted to evaluate the efficacy and safety of HAI of fluorouracil with leucovorin (HAI 5-FU/LV)
for patients with liver metastases from CRC. 
Methods: Fourteen patients with liver metastases from CRC who received HAI 5-FU/LV after failure of systemic
chemotherapy containing fluorouracil and leucovorin were identified and their medical records were reviewed. 
Results: Of 10 patients evaluable for response, one partial response, six stable disease, and three progressive
disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respective-
ly. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months
(range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic
toxicities occurred and one case of abdominal pain and two cases of oral mucositis were the only grade 3 non-
hematologic toxicities. Catheter-related complications occurred in three patients: one thrombosis, one infection,
and one displacement. 
Conclusions: HAI 5-FU/LV was well tolerated and showed modest efficacy for patients with liver metastases from
refractory CRC. Readministration of previously used chemotherapeutic agents via the hepatic artery could be an
effective salvage option and warrants further investigation in a prospective trial. (Korean J Intern Med
2011;26:82-88)
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INTRODUCTION
Nearly 50% of colorectal cancer (CRC) patients will
develop liver metastases at some point during their dis-
ease and it is the progression of the liver lesion that deter-
mines the overall life expectancy for patients with liver
metastases [1]. Surgical resection of liver metastases from
CRC is the only treatment modality with curative potential
and results in a 5-year overall survival (OS) rate of 20-
40% [2]. However, only 20% of patients with liver metas-
tases, depending on their comorbidities, have resectable
disease at diagnosis and are candidates for major surgery
[3]. Therapeutic strategies for unresectable liver metas-
tases consist of chemotherapy plus biologics such as beva-
cizumab or cetuximab, and then subsequent liver resec-
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ease. Even in the era of targeted agents such as cetuximab
[4,5] and bevacizumab [6], the hepatic resection rate
rarely exceeds 30-40%. Moreover, many patients cannot
receive targeted agents because of economic issues or
adverse events. This provides the impetus to develop regi-
mens that are more effective for patients with unre-
sectable liver metastases.
The liver has a dual blood supply system, the portal vein
to the healthy liver parenchyma and the hepatic artery to
the liver metastatic lesion [7]. Most cancer cells derive
their blood supply from hepatic arteries. This unique dif-
ferential blood supply of the liver provides the rationale
for locoregional treatment such as hepatic arterial infusion
(HAI) chemotherapy. For patients with unresectable liver
metastases from CRC, HAI provides higher concentra-
tions of chemotherapeutic agents in the hepatic artery.
HAI has been developed and tested over the past two
decades. It has been reported to produce a higher
response rate with better control of liver disease than con-
ventional chemotherapy but, for many reasons, has had
minimal impact on survival. HAI has no benefit for extra-
hepatic disease and has its own toxicity profile, including
biliary sclerosis, acalculous cholecystitis, and catheter-
related problems. Many of these results come from studies
with HAI of fluorodeoxyuridine (HAI FUDR) using a
hepatic arterial catheter placed during laparotomy [8].
FUDR is ideal for HAI because of its short half-life and
high liver extraction rate (> 90%), leading to a 100- to
400-fold ratio of hepatic-to-systemic drug exposure and a
response rate exceeding 50%, even without combination
with newer agents. However, HAI FUDR has limitations,
including biliary sclerosis, which is a dose-limiting toxicity
[9], and a disappointing control rate for extrahepatic dis-
ease [10]. HAI of fluorouracil with leucovorin (HAI 5-
FU/LV) demonstrated a response rate that was similar to,
or higher than, that obtained with HAI FUDR without the
associated hepatic toxicities and with a reduction in extra-
hepatic disease. A high local response rate, combined with
a significant reduction of extrahepatic disease, may
explain the superiority of HAI 5-FU/LV in prolonging
time to progression [11].
Because of the advantage of HAI for delivering higher
doses of anticancer agents directly into the affected organ,
HAI using previously administered systemic chemothera-
peutic agents could be another treatment option for
patients with refractory CRC with metastases confined to
the liver. To test this hypothesis, the present study was
conducted to evaluate the efficacy and safety of HAI 5-
FU/LV in patients with liver metastases from CRC who
were previously treated with systemic 5-FU-based
chemotherapy.
METHODS
Patients
All patients with liver metastases from CRC who
received HAI 5-FU/LV after failure of systemic 5-FU-
based chemotherapy between July 2004 and December
2009 were retrospectively enrolled in the present study.
Patients were identified from the prospectively main-
tained cancer registry from Seoul National University
Bundang Hospital electronic medical records. Data,
including patient and tumor characteristics, laboratory
values, treatment outcomes, and toxicity were collected
and analyzed retrospectively from patients’ medical
records.
Implantation of port system
After injection of a local anesthetic, the Seldinger tech-
nique was used to gain access to the right femoral artery.
Arteriography of the celiac trunk was performed to reveal
the hepatic arterial anatomy. The gastroduodenal artery
and the right gastric artery were embolized using steel
coils (Tornade, Cook, Bloomington, IL, USA) to prevent
gastroduodenal injury from the chemotherapeutic agents.
In patients with multiple hepatic arteries, all the hepatic
arteries except the largest one were embolized to redistrib-
ute the hepatic arterial flow so that a single indwelling
catheter could be used to infuse chemotherapeutic agents
to the entire liver. To avoid mechanical injury to the artery
by the infusion catheter, the “tip-fixation” technique was
used [12].
A 5F catheter (Port-A-Cath, Deltec, St. Paul, MN, USA)
with a side hole was inserted with the distal tip into the
gastroduodenal artery. The position of the side hole was
sited at the common hepatic artery, and then the distal tip
of the catheter was fixed within the gastroduodenal artery
using coils. The proximal end of the catheter was connect-
ed to the injection port and the device was implanted in a
subcutaneous pocket in the right inner thigh. To prevent
occlusion of the catheter, 10 mL (10,000 U) of heparin
solution was infused via the injection port after each cycle
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Chemotherapy administration
The 5-FU/LV treatment protocol consisted of hepatic
arterial administration using the infusion pump of 800
mg/m
2 5-FU infused over 24 hours on day 1-5 combined
with 200 mg/m
2 leucovorin on day 1-5. Treatment courses
were repeated every 4 weeks. Treatment was continued
until disease progression, toxicity prevented pursuit of
treatment, or patient refusal of treatment.
Efficacy and toxicity evaluation
Tumor size was measured using computed tomography
scans after every 2 or 3 cycles of treatment. The response
was assessed by medical oncologists at the time of treat-
ment according to the Response Evaluation Criteria in
Solid Tumors 1.0 [13] and was reviewed by an indepen-
dent radiologist blinded to the clinical outcome at the time
of retrospective review. Time to progression (TTP), time to
hepatic progression (THP), and time to extrahepatic pro-
gression (TEP) were calculated from the time of the first
HAI 5-FU/LV infusion. TTP was defined as progression of
disease at any site or death from any cause, THP was
defined as progression of disease in the liver, and TEP was
defined as progression outside the liver. Adverse events
were graded according to the Common Terminology
Criteria for Adverse Events (CTCAE ver. 3.0) before each
course of chemotherapy.
Statistical analysis
All time-related parameters were analyzed using the
Kaplan-Meier method. Data were expressed as means or
Table 1. Patient characteristics
Characteristics (n = 14) No. of patients (%)
Age, yr Median (range) 64.1 (32.9-76.3)
Sex Male 10 (71.4)
Female 4 (28.6)
Performance status (ECOG) 0 1 (7.1)
1 13 (92.9)
Primary site Colon 12 (85.7)
Rectum 2 (14.3)
Metastatic site Liver only 13 (92.9)
Liver and others 1 (7.1)
Type of liver metastases Synchronous 10 (71.4)
Metachronous 4 (28.6)
Bulk of liver metastases, % < 25 8 (57.1)
25-50 5 (35.7)
> 50 1 (7.1)
Surgery No surgery 1 (7.1)
Curative resection of primary site 4 (28.6)
Curative resection with liver metastases 2 (14.3)
Palliative surgery 7 (50)
No. of previous chemotherapy lines 1 1 (7.1)
2 5 (35.7)
3 6 (42.9)
4 2 (14.3)
Previous drug 5-FU 14 (100)
Oxaliplatin 14 (100)
Irinotecan 14 (100)
Capecitabine 8 (57.1)
Cetuximab 3 (21.4)
Bevacizumab 4 (28.6)
Local ablation therapy 4 (28.6)
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medians with ranges. All data parameters were compiled
using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
The present study was approved by the institutional
review board of Seoul National University Bundang
Hospital (IRB approval No. B-1003/095-103).
RESULTS
Patient characteristics
Fourteen patients with liver metastases received HAI 5-
FU/LV after failure of systemic chemotherapy. The medi-
an duration of follow-up was 8.4 months (range, 4.2 to
20). The median age of all patients was 64.1 years (range,
32.9 to 76.3) and the mean number of previously adminis-
tered systemic chemotherapies was 2.6 (range, 1 to 4). The
patients’ characteristics are listed in Table 1.
Thirteen patients had only hepatic metastases and one
patient had both hepatic and extrahepatic metastases. The
extrahepatic metastatic site was the lung. Two patients
underwent a hepatic metastasectomy, and four patients
underwent radiofrequency ablation (RFA) before receiv-
ing HAI 5-FU/LV. Most of the patients had been previous-
ly heavily treated. All 14 patients had previously received
chemotherapy containing 5-FU, oxaliplatin, and irinote-
can.
Efficacy
The mean number of treatment cycles was 4.1 (range, 1
to 7). Reasons for treatment discontinuation were disease
progression in 10 patients, patient refusal in two, severe
abdominal pain in one and catheter thrombosis in one.
The patient with severe abdominal pain could not com-
plete the first cycle and was therefore excluded from the
response evaluation. Two of four patients who had under-
gone RFA showed no measurable lesion and the other had
a small lesion less than 10 mm. One patient had a partial
response, six had stable disease, and three had progressive
disease. The overall response rate (RR) was 7% and the
disease control rate was 50%. Seven of the 13 patients who
had progression of their disease had progression of extra-
hepatic disease while their hepatic disease was stable. Two
patients with stable disease had progression of their dis-
ease during the chemo-off period. No patient in the pre-
sent study underwent hepatic resection after HAI 5-
FU/LV.
The median OS was 10.7 months (range, 8.5 to 12.8)
and the median TTP was 4.3 months (range, 2.9 to 5.6).
The median THP was 5.8 months (range, 4.7 to 6.9) and
the median TEP was 5.8 months (range, 2.3 to 9.2). Fig. 1
illustrate the TTP, THP, and TEP. Among the seven
patients who experienced earlier progression of extrahep-
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Figure 1. (A) Time to progression in patients who received HAI 5-FU/LV. (B) Time to hepatic progression and extrahepatic progression in
patients who received HAI 5-FU/LV. HAI 5-FU/LV, hepatic arterial infusion of fluorouracil with leucovorin; THP, time to hepatic progres-
sion; TEP, time to extrahepatic progression.
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atic disease as opposed to hepatic disease, five presented
with de novo extrahepatic metastases, one who had an ini-
tial lung metastasis experienced progression of that lung
metastasis, and one showed local recurrence. Nine of the
14 patients underwent additional systemic chemotherapy
after their disease progression. Among the seven patients
with earlier extrahepatic progression, four received sal-
vage chemotherapy, two received palliative care, and one
patient was lost to follow-up. Five of six patients who
experienced earlier hepatic disease progression under-
went salvage chemotherapy and the other received pallia-
tive care. 
Capecitabine, S-1, oxaliplatin, irinotecan, oratecan,
cetuximab, and bevacizumab were used in salvage therapy
as single agents or in combination. One patient received
oral S-1 plus HAI oxaliplatin but progressed. Five of the 14
patients did not undergo further systemic chemotherapy
because of their poor performance status or refusal to
receive further treatment.
Toxicity
No treatment-related deaths were reported. The most
frequent nonhematologic toxicity was oral mucositis,
which occurred in 11 patients, with grade 3 oral mucositis
in two patients. Hematologic toxicity of any grade was
mild and no episode of febrile neutropenia was reported.
No biliary sclerosis or cholangitis was observed (Table 2).
Three catheter-related complications were reported.
One patient had catheter thrombosis and another had
catheter displacement that led to removal of the hepatic
arterial catheter and discontinuation of HAI. The other
patient had a catheter-related infection, which was treated
with antibiotics, and continued HAI 5-FU/LV.
The median dose intensity of infused 5-FU was 915.0
mg/m
2/wk (range, 682.2 to 1098.0) and the relative dose
intensity was 91.5%. Five patients had the same daily dose
of HAI 5-FU/LV for 4 instead of 5 days, which led to the
reduction of the dose to 80% of that planned.
DISCUSSION
In our study, HAI 5-FU/LV in heavily treated patients
with unresectable liver metastases from CRC demonstrat-
ed moderate efficacy and toxicity. Although all patients
had failed previous systemic chemotherapy containing 5-
FU, oxaliplatin, and irinotecan, they showed a TTP of 4.3
months and a disease control rate of 50%. These findings
are similar to those of other second-line systemic
chemotherapies. Prospective randomized phase III trials
of first-line modern chemotherapy FOLFOX [14] and
FOLFIRI [15] before the era of targeted therapy reported
response rates of 50-56% and complete resection rates of
4-21%. Response rates to second-line chemotherapy were
even lower [15]. Second-line FOLFIRI and FOLFOX-6
achieved response rates of 4% and 15% and progression-
free survivals of 2.5 and 4.2 months, respectively. Our
results suggest that HAI 5-FU/LV might be effective in
increasing the TTP in patients who experienced failure of
previous systemic 5-FU by delivering a higher concentra-
tion of drug directly to metastatic lesions. This hypothesis
could be expanded to HAI with other active agents such as
oxaliplatin and irinotecan after systemic failure of the
same agents. HAI of oxaliplatin or irinotecan has demon-
strated efficacy and feasibility as a salvage treatment
modality. HAI of irinotecan, 5-FU, and oxaliplatin in pre-
viously treated patients resulted in a 33% objective
response rate and a median progression-free survival
(PFS) of 6 months [16]. HAI of oxaliplatin with systemic
infusion of 5-FU/LV in pretreated patients reported an
objective response rate of 55% and a median PFS of 7
months [17].
The present study showed that the response rate to HAI
5-FU/LV was lower than the previously reported response
rates to hepatic arterial chemotherapy of 22-48%
[11,18,19]. The median TTP was similar to that reported by
Bouchahda et al. (4.5 months) [20] but inferior to those
reported in other studies (12-24 months) [11,18,19]. These
different results could have arisen from differences in
study populations. Previous studies with heavily treated
Table 2. Common toxicities
Toxicity (n = 14) All grades Grade 3
Diarrhea 1 (7.1) 0 (0)
Vomiting 6 (42.9) 0 (0)
Oral mucositis 11 (78.6) 2 (14.3)
Abdominal pain 5 (35.7) 1 (7.1)
Neutropenia 2 (14.2) 0 (0)
Anemia 2 (14.3) 0 (0)
Thrombocytopenia 0 (0) 0 (0)
AST/ALT elevation 7 (50) 0 (0)
ALP elevation 7 (50) 0 (0)
Hyperbilirubinemia 3 (21.4) 0 (0)
Values are presented as number (%).
AST, aspartate transaminase; ALT, alanine transaminase; ALP, alka-
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patients reported a median TTP similar to the current
study [20]. Other studies with chemotherapy-naïve
patients reported higher response rates and longer TTP
[11,18,19]. In the current study, the median TEP was equal
to, or longer than, the THP. This finding could be attrib-
uted to the use of 5-FU and LV as the HAI agent.
Neurotoxicity (not reported) and hematologic toxicities
(0-14.2%) were less common than for second-line sys-
temic chemotherapy with similar 5-FU dose intensity [15].
The frequency of all and grade 3 oral mucositis (78.6%
and 14.3%, respectively) in patients treated with HAI 5-
FU/LV was similar to that observed in patients treated
with systemic infusion of 5-FU/LV (75% and 11.5%,
respectively) [11]. Local complications such as hyperbiliru-
binemia and alkaline phosphatase elevations (21%) were
lower and milder than were those with HAI FUDR (38%)
[19]. In contrast to FUDR, which has a hepatic extraction
rate of more than 95%, 5-FU can achieve a high intrahep-
atic concentration while maintaining a significant sys-
temic concentration because it has a hepatic extraction
ratio of 10-80% depending on the infusion dose rate [21].
These pharmacokinetic features could explain the efficacy
and toxicity of HAI 5-FU/LV.
Catheter-related complications were catheter thrombo-
sis, displacement, and infection. The rate of these compli-
cations was lower than in other studies [22,23]. A surgi-
cally implanted port catheter system results in a higher
port failure rate than a radiologically implanted system
[24] and can result in procedure-related morbidities that
can lead to a lack of survival benefit from treatment [25].
Radiologic placement of the catheter in the current study
contributed to the lack of procedure-related complica-
tions.
This is a retrospective study and has limitations because
of its small sample size. However, the results of the pre-
sent study demonstrate that HAI 5-FU/LV is feasible, has
few toxicities or catheter-related complications, and could
be an alternative salvage option for patients who fail with
treatment using systemic infusion of 5-FU/LV. The results
of the present study suggest that readministration via the
hepatic artery of a chemotherapeutic agent to which
patients have already been exposed could be a feasible sal-
vage option for patients with refractory CRC, with metas-
tases confined to the liver. Thus, prospective studies eval-
uating the potential of hepatic arterial chemotherapy are
warranted.
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